Review

Drug Resistance (Dapsone, Rifampicin, Ofloxacin) and Resistance-Related Gene Mutation Features in Leprosy Patients: A Systematic Review and Meta-Analysis

Xiang Li 1,†, Guoli Li 2,†, Jing Yang 1, Guangjie Jin 2, Yuting Shao 1, Yunhui Li 1, Pingmin Wei 1,* and Lianhua Zhang 1,2,*

1 Department of Epidemiology and Health Statistics, School of Public Health, Southeast University, Nanjing 210009, China
2 Department of Chronic Infectious Disease Control and Prevention, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China
* Correspondence: 101010014@seu.edu.cn (P.W.); zhanglh@jscdc.cn (L.Z.)
† These authors contributed equally to this work.

Abstract: Dapsone (DDS), Rifampicin (RIF) and Ofloxacin (OFL) are drugs recommended by the World Health Organization (WHO) for the treatment of leprosy. In the context of leprosy, resistance to these drugs occurs mainly due to mutations in the target genes (Folp1, RpoB and GyrA). It is important to monitor antimicrobial resistance in patients with leprosy. Therefore, we performed a meta-analysis of drug resistance in Mycobacterium leprae and the mutational profile of the target genes. In this paper, we limited the study period to May 2022 and searched PubMed, Web of Science (WOS), Scopus, and Embase databases for identified studies. Two independent reviewers extracted the study data. Mutation and drug-resistance rates were estimated in Stata 16.0. The results demonstrated that the drug-resistance rate was 10.18% (95% CI: 7.85–12.51). Subgroup analysis showed the highest resistance rate was in the Western Pacific region (17.05%, 95% CI:1.80 to 13.78), and it was higher after 2009 than before [(11.39%, 7.46–15.33) vs. 6.59% (3.66–9.53)]. We can conclude that the rate among new cases (7.25%, 95% CI: 4.65–9.84) was lower than the relapsed (14.26%, 95 CI%: 9.82–18.71). Mutation rates of Folp1, RpoB and GyrA were 4.40% (95% CI: 3.02–5.77), 3.66% (95% CI: 2.41–4.90) and 1.28% (95% CI: 0.83–2.63) respectively, while the rate for polygenes mutation was 1.73% (0.83–2.63). For further analysis, we used 368 drug-resistant strains as research subjects and found that codons (Ser, Pro, Ala) on RpoB, Folp1 and GyrA are the most common mutation sites in the determining region (DRDR). In addition, the most common substitution patterns of Folp1, RpoB, and GyrA are Pro→Leu, Ser→Leu, and Ala→Val. This study found that a higher proportion of patients has developed resistance to these drugs, and the rate has increased since 2009, which continue to pose a challenge to clinicians. In addition, the amino acid alterations in the sequence of the DRDR regions and the substitution patterns mentioned in the study also provide new ideas for clinical treatment options.

Keywords: leprosy; drug resistance; genes mutations; dapsone; rifampicin; ofloxacin

1. Introduction

Leprosy is a chronic infectious disease caused by M. leprae or M. lepromatosis, which may lead to irreversible damage to the skin, peripheral nerves, and even disability. The incubation period of the slow-growing viruses varies from 2 to 11 years, making treatment extremely difficult [1]. According to the WHO weekly report, there were 208,641 new cases around the world during 2018, and the transmission of leprosy continues in more than 100 countries, particularly in India (120,334 cases), Brazil (28,660 cases), and Indonesia (17,017 cases) [2,3].

Since 1940, dapsone (DDS) has been considered the most effective antibacterial and anti-inflammatory drug against Mycobacterium leprae. Nevertheless, the first DDS-resistant
strain of *Mycobacterium leprae* was discovered in 1964 [4]. In 1981, WHO introduced multidrug therapy (MDT) for leprosy as a priority strategy to reduce drug resistance: the first-line drugs (rifampicin, ampicillin, and clofazimine) and second-line drugs (minocycline, ofloxacin, and clarithromycin). WHO also recommends a 1-year MDT course for multibacillary (MB) patients and a 6-month course for Paucibacillary (PB) [5]. Over time, new cases have been largely eliminated. In 1996, however, the first resistant strain to DDS, RIF, and OFL was identified. Relapse and recurrence cases remain a global public health problem associated with non-compliance with MDT or antimicrobial resistance (AMR), especially in MB patients [6–8]. As a first-line drug, there were few strains resistant to clofazimine. MmpS5-MmpL5 is the most important RND transporter protein in Mycobacterium tuberculosis, and its overexpression was associated with resistance to azoles (e.g., clofazimine). Nevertheless, MmpS5-MmpL5 is absent in *Mycobacterium leprae*, which partly explains the rarity of clofazimine-resistant strains [9].

The failure of *Mycobacterium leprae* to grow in vitro hinders the investigation of AMR. There are two approaches available to detect drug resistance at present. The first one is to inoculate *Mycobacterium leprae* onto the foot pads of mice for culture and extract the tissues for testing [10]. In 1967, this method was used to detect drug resistance for the first time, such as DDS and fluoroquinolones. However, the growth of *Mycobacterium leprae* is slow and a long period of time (>1 year) is required to obtain the desired results, rendering the process both time-consuming and laborious. The second approach is to detect mutations by PCR-DNA sequencing. Studies have shown that mutations in the drug-resistance determining region (DRDR) in the FolP1, RpoB, and GyrA genes are responsible for resistance to DDS, RIF, and OFL [11,12]. The molecular-based detection method is more effective than the classic footpad experiment, reducing the turnaround time for diagnosis from months to hours. It has been shown that the DRDR region is situated between 44–64 loci of FolP1, 439–459 of RpoB, and 81–101 of GyrA (Figure 1) [13]. To date, many loci mutations associated with drug resistance have been identified. For instance, mutations within codon 53 (ACC→ATC) of the DRDR region of FolP1, ACC→ATC/GGC→GAC of RpoB, and mutations in codon 55/91 of GyrA confer drug resistance to *Mycobacterium leprae* [14–16].

![Figure 1. Resistance determining region (DRDR) sequences of target genes. FolP1, RpoB, and GyrA confer resistance to DDS, RIF and OFL, respectively, and the numbers indicate codon positions.](image)

There are many possible mechanisms of drug resistance in leprosy, such as changes in cell wall permeability and regulation of pump proteins. Genetic mutation detection remained the most recognized method with a high degree of sensitivity [17]. So far, although many papers have been published on the detection of drug resistance in *Mycobacterium leprae*, no publications have studied genetic mutations and amino acid substitutions in this virus. In this study, we investigated the global drug-resistance rate and gene mutation features of *Mycobacterium leprae* based on a meta-analytic approach. The paper aims to provide new ideas for the development of strategies to eliminate drug resistance and select more appropriate clinical treatment drug options.

2. Methods

2.1. Database and Search Strategy

The review was conducted in accordance with the established PRISMA protocol (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) [18]. The review
protocol has been registered in the International Prospective Register of Systematic Reviews (PROSPERO) (https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022340709, accessed on 2 October 2022). We limited the publication period from 1 January 2000 to 10 May 2022 and searched PubMed/MEDLINE, Web of Science (WOS), Scopus, and Embase databases for identified studies. Medical subject terms (MeSH) and free words were used as keywords for the literature search. In addition, the references in the identified papers were further screened for a relevant study. The main research keywords were “leprosy”, “Hansen’s Disease”, “resist”, “resistance”, “genes”, “mutations” and related terms. Finally, 1098 studies were identified from the database. The detailed database search strategy is shown in Supplementary File S1.

2.2. Study Selection

Duplicates were classified, annotated, and removed after exporting the retrieved papers to the reference software EndNote v.9.0 (Thomson Reuters, Stamford, CT, USA). Two researchers conducted the screening independently (Xiang Li, and Guoli Li), if disagreement still exists, a third author should be consulted. Finally, we evaluated the full text of the articles according to the inclusion and exclusion criteria.

2.3. Inclusion and Exclusion of Studies

Detailed inclusion and exclusion criteria were as follows. Inclusion criteria: (1) Drug resistance was detected by DNA sequencing recommended by WHO; (2) The studies that have reported mutations at target genes (Folp1, RpoB, and GyrA); (3) The studies should include accurate sample sizes (drug-resistant or none) and complete outcomes. (4) The included studies were primarily English-language reports (Full text). Exclusion criteria: (1) Diagnostic evaluation of experimental studies; (2) Animal-related studies; (3) Studies of low quality such as multiple publications, unpublished or unavailable full-text articles; (4) Reviews, conference reports, case reports, or social commentaries.

2.4. Data Extraction and Quality Assessment

Data were extracted independently by two investigators, and any disputes were resolved through discussion. The following information was extracted from the identified papers: region of the study, year of the study, sample type, study period, number of Mycobacterium leprae isolates, drug-resistance rates of Mycobacterium leprae isolates, gene mutation frequency, and locus mutation characteristics. The Joanna Briggs Institute recommended critical quality assessment inventory was used to assess the quality of all included studies (JBI scale) [18]. The results of the quality evaluation criteria are shown in the Supplementary File S2.

2.5. Statistical Analysis

Descriptive statistics were used to describe the overall search results and features of included studies with Microsoft Excel 2021. The extracted data were imported from Excel into Stata version 15.0. Forest plots evaluated the heterogeneity of the studies with the inverse variance (I^2) statistic and Statistical quantities (χ^2). Considering the differences among studies (I^2 > 50%), the random effects model was applied at the 95% confidence level. Otherwise, a fixed effects model was used for I^2 < 50%. Subgroup analysis was performed based on the study region, clinical treatment, drug-resistant strains, recurrence condition, study period, and sample size. In addition, we calculated the frequency of gene mutations and analyzed the probability of mutation at each locus with resistant strains. Finally, publication bias was assessed using funnel plots. The authors have provided the data extracted from the spreadsheet in the Supplementary File S3.
3. Results
3.1. Characteristics and Quality Assessment of Included Studies

During the initial systematic search, 1098 studies were identified from the database. After eliminating duplicate papers by title filtering and excerpting, 113 articles remained. Articles with scores >5 were included based on predetermined criteria and the results of the JBI scale scores. Finally, there were 25 articles in total included in this meta-analysis after full-text evaluation. Figure 2 shows the search and selection process of the literature.

Figure 2. Flow chart of literature screening.

Table 1 and the Supplementary File S3 show the study characteristics and quality assessment. As a result, a total of 25 papers were included in this review, and there were 4349 leprosy patients included. Of these, 4128 were successfully amplified (94.92%), and 368 drug-resistant strains were obtained (RIF: 113, DDS: 145, OFL: 65, MDR: 57). A total of 6 papers were conducted before 2009, and 14 were conducted after 2009, while the remaining five papers were conducted outside of this temporal delineation criterion or without notification of the time of collection. A total of 20 (80%) papers were considered high quality because they provided accurate information on the number of drug-resistant patients among relapsed cases. Sixteen articles also provided accurate numbers of drug-resistant strains among MB patients (2394 cases) and PB patients (416 cases). Regarding regional distribution, 10 studies were from Southeast Asia, 8 from the Americas, 5 from the Western Pacific, and 1 from Europe (France) and Africa (Guinea). The study distribution
map is shown in Figure 3. All articles reported the features of target gene mutations (Folp1, RpoB, GyrA), while 2 papers only reported RIF/RpoB.

Table 1. The study characteristics and quality assessment of 25 included papers in this systematic review.

| Author           | Publication Year | Study Period | Study Region    | Total Positive Samples | Percentage * (%) | MDR | Folp1 (n/%) | RpoB (n/%) | GyrA (n/%) | JBI Scores |
|------------------|------------------|--------------|-----------------|------------------------|------------------|-----|------------|------------|------------|------------|
| Charlotte et al. | 2016             | 2012–2015    | Africa          | 24                     | 100.00           | 0   | 3 (12.50) | 1 (4.17)  | 0 (0.00)  | 6          |
| Masanori et al.  | 2011             | 2004–2009    | Asia            | 290                    | 68.56            | 0   | 19 (10.16) | 7 (4.29)  | 0 (0.00)  | 6          |
| Adalgiza et al.  | 2012             | 2006–2008    | South America   | 145                    | 100.00           | 3   | 3 (5.26)  | 4 (7.02)  | 2 (3.51)  | 7          |
| Liu et al.       | 2015             | 2007–2014    | Asia            | 85                     | 100.00           | 3   | 1 (1.49)  | 5 (8.77)  | 21 (31.34) | 6          |
| Williams et al.  | 2013             | 2011–2012    | North America   | 39                     | 100.00           | 0   | 2 (5.13)  | 1 (2.56)  | 0 (0.00)  | 6          |
| Mallika et al.   | 2014             | 2009–2013    | Asia            | 111                    | 79.29            | 2   | 9 (8.11)  | 4 (3.60)  | 9 (9.01)  | 6          |
| Rosa et al.      | 2020             | 2009–2013    | South America   | 37                     | 100.00           | 12  | 16 (59.26)| 15 (60.00)| 2 (7.41)  | 6          |
| Lavana et al.    | 2015             | 2013–2014    | Asia            | 215                    | 93.02            | 0   | 1 (0.47)  | 7 (3.26)  | 0 (0.00)  | 7          |
| Narang et al.    | 2021             | 2019–2020    | Asia            | 61                     | 100.00           | 2   | 5 (8.20)  | 6 (9.84)  | 1 (1.64)  | 7          |
| Niranjan et al.  | 2020             | 2007–2018    | Asia            | 77                     | 92.77            | 2   | 2 (2.60)  | 1 (1.30)  | 5 (6.49)  | 6          |
| Martha et al.    | 2014             | 1985–2004    | South America   | 941                    | 100.00           | 6   | 4 (0.43)  | 27 (2.87) | 10 (1.38) | 6          |
| Camilo et al.    | 2016             | 2004–2013    | South America   | 243                    | 100.00           | 1   | 5 (2.06)  | 5 (2.06)  | 1 (0.41)  | 6          |
| Lavana et al.    | 2018             | 2009–2016    | Asia            | 250                    | 100.00           | 17  | 16 (6.40) | 11 (4.40) | 10 (4.00) | 6          |
| Chokkakula et al.| 2019             | 2013–2017    | Asia            | 290                    | 100.00           | 2   | 8 (2.76)  | 1 (0.34)  | 8 (2.76)  | 6          |
| You et al.       | 2005             | NR           | Asia            | 104                    | 100.00           | 5   | 20 (19.23)| 3 (2.88)  | 1 (0.96)  | 6          |
| Chen et al.      | 2019             | 2003–2011    | Asia            | 76                     | 100.00           | 1   | 19 (25.00)| 0 (0.00)  | 1 (1.32)  | 7          |
| Masanori et al.  | 2010             | NR           | North America   | 38                     | 100.00           | 0   | 0 (0.00)  | 2 (5.26)  | 1 (2.63)  | 6          |
| Chauffour et al. | 2018             | 2001–2015    | Europe          | 160                    | 86.96            | 0   | 13 (8.13)| 3 (1.88)  | 2 (1.25)  | 6          |
| Singh et al.     | 2018             | NR           | Asia            | 78                     | 84.78            | 0   | 0 (0.00)  | 8 (32.00) | 7          |
| Masanori et al.  | 2007             | 2000–2006    | Asia            | 305                    | 100.00           | 0   | 6 (4.58)  | 9 (11.54) | 0 (0.00)  | 6          |
| Matilde et al.   | 2014             | 2009–2011    | South America   | 197                    | 100.00           | 1   | 0 (0.00)  | 4 (5.26)  | 0 (0.00)  | 5          |
| Singh et al.     | 2011             | NR           | South America   | 233                    | 100.00           | 0   | 2 (0.86)  | 1 (0.43)  | 0 (0.00)  | 7          |
| Abu et al.       | 2015             | 2007–2009    | Asia            | 50                     | 100.00           | NS  | NS        | 2 (4.00)  | NS         | 6          |
| Sundeep et al.   | 2014             | NR           | Asia            | 60                     | 100.00           | NS  | NS        | 10 (16.67)| NS         | 6          |
| Shi et al.       | 2022             | 2018–2021    | Asia            | 34                     | 100.00           | 1   | 3 (1.33)  | 0 (0.00)  | 3.13       | 6          |

%: Positive Sample; NS: Not studied; MB: Multibacillary; PB: Paucibacillary. *: Percentage of positive samples out of all samples.

3.2. Drug Resistance Analysis of Mycobacterium leprae

We calculated the drug-resistance rate of Mycobacterium leprae, and due to its heterogeneity $P = 89.7\% > 50\%$, a random effects model was adopted for analysis. As shown in Figure 4, the resistance rate of RIF, DDS, and OFL was 10.18% (95% CI: 7.85 to 12.51).
The study characteristics and quality assessment of 25 included papers in this systematic review.

Table 1. The distribution of countries covered in the 25 papers. Created with Mapchart (https://www.mapchart.net/, accession on 24 August 2022).

| Study ID       | ES (95% CI) | %  | Weight |
|----------------|-------------|----|--------|
| Charlotte et al (2016) | 16.67 (1.76, 31.58) | 1.70 |
| Mosenx et al (2011) | 6.65 (3.70, 9.49) | 5.15 |
| Adalga et al (2012) | 2.76 (0.60, 5.42) | 5.20 |
| Liu et al (2015) | 17.75 (21.87, 41.06) | 2.78 |
| Williams et al (2013) | 7.69 (4.67, 10.66) | 3.25 |
| Lavani et al (2014) | 18.02 (10.87, 25.17) | 3.66 |
| Rossa et al (2020) | 45.98 (28.89, 62.00) | 1.83 |
| Lavani et al (2015) | 3.50 (0.66, 6.05) | 5.23 |
| Narang et al (2021) | 16.39 (7.10, 25.68) | 2.96 |
| Niranjan et al (2020) | 7.79 (1.81, 13.79) | 4.08 |
| Martha et al (2014) | 4.14 (2.87, 5.42) | 5.49 |
| Camilo et al (2015) | 4.12 (1.62, 6.61) | 5.24 |
| Loven et al (2013) | 26.40 (22.81, 33.99) | 4.32 |
| Chokskulana et al (2019) | 6.21 (3.43, 8.98) | 5.17 |
| You et al (2005) | 19.23 (11.66, 26.81) | 3.51 |
| Chen et al (2019) | 25.00 (15.26, 34.74) | 2.83 |
| Mosenx et al (2010) | 7.89 (4.85, 10.34) | 3.18 |
| Chaflour et al (2018) | 11.25 (6.35, 16.15) | 4.48 |
| Singh et al (2018) | 10.26 (3.62, 16.99) | 3.81 |
| Mosenx et al (2007) | 7.57 (4.85, 10.89) | 5.10 |
| Matll et al (2014) | 2.03 (0.06, 4.00) | 5.36 |
| Singh et al (2011) | 1.28 (0.15, 2.74) | 5.46 |
| Abu et al (2015) | 4.00 (1.45, 6.45) | 4.28 |
| Sundep et al (2014) | 16.67 (7.74, 26.10) | 2.92 |
| Shi et al (2022) | 5.68 (2.03, 13.79) | 3.46 |
| Overall | 10.18 (7.85, 12.51) | 100.00 |

Figure 3. The distribution of countries covered in the 25 papers. Created with Mapchart (https://www.mapchart.net/, accession on 24 August 2022).

Figure 4. The forest plot of drug—resistance rates in Mycobacterium leprae. ES = drug—resistance rate, 95% CI = confidence interval. The incidence and 95% CI of the drug—resistance rate for each study are represented. Forest plot of drug—resistance rates of Mycobacterium leprae isolates in studies meeting inclusion criteria (n = 25) [14,19–42].

A subgroup analysis was performed due to the large heterogeneity in this study. The study areas were divided into six parts based on the WHO regional classification criteria.
criteria. The results show that the highest resistance rate was found in the Western Pacific region (17.05%, 95% CI: 1.80–13.78). However, only 1 article in Europe and 1 in Africa was included, with a resistance rate of 11.25% (95% CI: 6.35–16.15) and 16.67% (95% CI: 1.76–31.58), respectively. We have also calculated the resistance rates between different drugs. The DDS rate was the highest (3.98%, 95% CI: 2.69–5.28), and the rate of MDR was 1.73% (95% CI: 0.83–2.63). After dividing patients into new and relapse groups, we found that the resistance rate was 7.25% (4.65–9.84) in new cases, which was lower than the rate of 14.26% (9.82–18.71) in relapsed patients. Temporal subgroups reported higher drug resistance after 2009 (11.39% vs. 6.59%). In addition, studies with <100 isolates had higher resistance rates than those with more than 100 isolates. Details of the results are shown in Table 2.

Table 2. Summarized estimates of drug resistance stratified by region (according to WHO criteria), different drugs, clinical treatment, relapse or new cases, and sample size variables.

| Factor                        | Study/n | Cases/Positive Samples(n) | ES(%)/95% CI | I² (%) | Heterogeneity Chi-Squared | p   |
|-------------------------------|---------|---------------------------|--------------|--------|--------------------------|-----|
| WHO Region                    |         |                           |              |        |                          |     |
| Southeast Asia                | 10      | 177/1482                  | 11.43 (9.19–16.81) | 88.8%  | 80.57                    | 0.00 |
| Americas                      | 8       | 83/1873                   | 4.19 (1.89–6.50) | 82.6%  | 40.13                    | 0.00 |
| Western pacific               | 5       | 86/389                    | 17.05 (7.17–26.93) | 90.4%  | 41.60                    | 0.97 |
| Africa                        | 1       | 4/24                      | 16.67 (1.76–31.58) | -      | -                        | -   |
| Europe                        | 1       | 18/160                    | 11.25 (6.35–16.15) | -      | -                        | -   |
| Mediterranean                 |         |                           |              |        |                          |     |
| Different drugs               |         |                           |              |        |                          |     |
| DDS                           | 20      | 145/3325                  | 3.98 (2.69–5.28) | 86.2%  | 137.19                   | 0.00 |
| RIF                           | 19      | 113/3352                  | 2.97 (1.94–4.00) | 70.6%  | 61.25                    | 0.00 |
| OFL                           | 15      | 65/2609                   | 1.90 (0.97–2.83) | 72.6%  | 51.19                    | 0.00 |
| MDR                           | 13      | 57/2617                   | 1.73 (0.83–2.63) | 71.7%  | 42.35                    | 0.00 |
| Relapsed or new cases         |         |                           |              |        |                          |     |
| New                           | 14      | 128/1960                  | 7.25 (4.65–9.84) | 86.1%  | 93.74                    | 0.00 |
| Relapse                       | 17      | 119/1248                  | 14.26 (9.82–18.71) | 82.9%  | 87.83                    | 0.00 |
| Clinical Treatment            |         |                           |              |        |                          |     |
| MB                            | 15      | 175/2394                  | 8.97 (6.29–11.65) | 82.4%  | 79.57                    | 0.00 |
| PB                            | 5       | 25/481                    | 8.09 (2.15–14.02) | 50.2%  | 8.03                     | 0.09 |
| No of isolation               |         |                           |              |        |                          |     |
| ≥100                          | 13      | 257/3469                  | 7.69 (5.21–10.18) | 91.5%  | 141.26                   | 0.00 |
| <100                          | 13      | 111/659                   | 15.00 (9.45–20.55) | 80.4%  | 56.15                    | 0.00 |
| Study period                  |         |                           |              |        |                          |     |
| After 2009                    | 14      | 180/1652                  | 11.39 (7.46–15.33) | 91.6%  | 155.50                   | 0.00 |
| Before 2009                   | 5       | 106/1785                  | 6.59 (3.66–9.53) | 82.3%  | 22.58                    | 0.00 |
| Overall                       | 25      | 386/4128                  | 10.18 (7.85–12.51) | 89.7%  | 232.74                   | 0.00 |

ES = drug-resistance rate, 95% CI = confidence interval.

3.3. Mutation Analysis of Drug Resistance Genes in Mycobacterium leprae

In this review, 20, 22, and 16 articles studied Folp1, RpoB, and GyrA genes 139, 129, and 83 times. The results showed that the mutation rates of Folp1, RpoB and GyrA were 4.40% (95% CI: 3.02–5.77), 3.66% (95% CI: 2.41–4.90) and 1.28% (95% CI: 0.87–1.71), respectively, as it was shown in Table 3.

Table 3. Mutation rate of drug-resistance genes.

| Gene  | Study/n | Mutations(n) | ES%  | 95% CI       | I² (%) | Heterogeneity Chi-Squared | p   |
|-------|---------|--------------|------|--------------|--------|--------------------------|-----|
| Folp1 | 20      | 139          | 4.40 | 3.02–5.77    | 89.2   | 167.07                   | 0.00 |
| RpoB  | 22      | 129          | 3.66 | 2.41–4.90    | 80.2   | 105.84                   | 0.00 |
| GyrA  | 16      | 83           | 1.28 | 0.87–1.71    | 76.4   | 59.44                    | 0.00 |

ES = drug-resistance rate, 95% CI = confidence interval.
Based on the 382 drug-resistant strains, it can be seen that the RpoB gene involved the largest variety of mutations and the GyrA the least, as it was shown in Table 4. In the DRDR region of RpoB, the mutation rate in the codon encoding Ser was 54.17% (95% CI: 53.02–69.40), indicating that Ser had the highest probability of mutation. The codon encoding Pro has the highest rate of mutation (83.97%, 95% CI: 77.58 to 90.37) in Folp1. The most common mutation loci in GyrA was Alanine (Ala), with a probability of 75.18% (95% CI: 68.54 to 88.62). In addition, there were insufficient data from the studies to analyze rare mutations, such as Arg in RpoB, Ala in Folp1, and Leu in GyrA.

| Gene/Amino Acids | Events/Mutations(n) | ES% | 95% CI | $I^2$ (%) | Heterogeneity Chi-Squared | $p$ |
|------------------|---------------------|-----|--------|----------|-------------------------|-----|
| **RpoB (codon: 439–459)** | | | | | | |
| Ser (Serine) | 10 | 58/73 | 54.17 | 53.02–69.40 | 79.10 | 43.06 | 0.000 |
| Thr (Threonine) | 3 | 5/24 | 19.54 | 3.88–35.20 | 0.00 | 0.62 | 0.733 |
| Asp (Aspartic) | 8 | 13/92 | 12.32 | 5.67–18.98 | 0.00 | 0.64 | 0.913 |
| Gln (Glutamine) | 6 | 12/51 | 19.29 | 5.67–18.98 | 0.00 | 0.55 | 0.909 |
| Ala (Alanine) | 3 | 6/21 | 24.52 | 0.76–20.27 | 0.00 | 0.55 | 0.909 |
| Leu (Leucine) | 3 | 6/21 | 24.52 | 0.76–20.27 | 0.00 | 0.55 | 0.909 |
| His (Histidine) | 2 | 4/37 | 10.52 | 0.76–19.86 | 0.00 | 0.55 | 0.909 |
| Val (Valine) | 4 | 4/36 | 10.10 | 0.33–19.86 | 0.00 | 0.55 | 0.909 |
| Gly (Glycine) | 4 | 7/28 | 25.40 | 0.33–19.86 | 0.00 | 0.55 | 0.909 |
| Phe (Phenylalanine) | 2 | 2/18 | 11.11 | 0.33–19.86 | 0.00 | 0.55 | 0.909 |
| **Folp1 (codon: 44–64)** | | | | | | |
| Pro (Proline) | 10 | 87/112 | 77.58–90.37 | 37.80 | 14.47 | 0.107 |
| Thr (Threonine) | 11 | 44/133 | 31.36 | 5.32–57.41 | 95.60 | 229.51 | 0.000 |
| Arg (Arginine) | 2 | 2/37 | 5.32 | −0.32–19.86 | 0.00 | 0.55 | 0.909 |
| **GyrA (codon: 81–101)** | | | | | | |
| Ala (Alanine) | 5 | 31/68 | 75.18 | 68.54–88.62 | 63.60 | 11.00 | 0.027 |
| Gly (Glycine) | 3 | 7/24 | 26.00 | 10.14–41.88 | 90.80 | 3.38 | 0.185 |
| Ser (Serine) | 2 | 7/20 | 35.08 | 7.59–62.57 | 90.80 | 3.38 | 0.185 |

ES = drug-resistance rate, 95% CI = confidence interval.

3.4. Subgroup Analysis of Site Mutation Patterns at Folp1, RpoB, and GyrA

A random effects model was used to conduct a subgroup analysis of the codon with the highest mutation rate. As the result indicated, the most common mutation pattern in Folp1 was Pro→Leu, followed by Pro→Arg, with an occurrence of 41.04% (95% CI: 22.76–59.31) and 36.80% (95% CI: 22.76–59.31). On the DRDR region of RpoB, Ser→Leu was the most common mutation pattern in Folp1 (42.95%, 95% CI: 22.65–63.25), followed by Ser→Phe (ES: 35.08%, 95% CI: 7.59–62.57). We did not perform a subgroup analysis for Ala, since a majority of the included publications were Ala→Val (92.65%, 63/68), as shown in Figure 5.

3.5. Publication Bias Analysis

The funnel plots were used to assess publication bias, and the standard error was plotted against the gene mutations. The results showed a symmetrical distribution, indicating the absence of publication bias, as it was shown in Figure 6. The main causes of bias are the following. First, leprosy has been completely eradicated in some areas, with an insufficient number of papers available for research. Second, positive results may be more easily published. In order to avoid publication bias and heterogeneity, we attempted to reduce their impact on the analysis through random effects models and subgroup analysis but were still unable to eliminate the impact on the interpretation of the pooled results.
Figure 5. The Ser, Pro mutation forest plot. (a) The forest plot of the Ser mutation in RpoB. (b) The forest plot of the Pro mutation in Folp1 [14,20,21,24,25,27–32,34,35,37,38].
Figure 6. Funnel plot of gene mutation in Mycobacterium leprae. (a) Funnel plot of Folp1; (b) Funnel plot of RpoB; (c) Funnel plot of Folp1.

4. Discussion

Intensive chemical treatment has led to a significant reduction in leprosy patients. However, the emergence of multidrug-resistance (MDR) remains a major public health problem in leprosy control. Thus, we conducted a meta-analysis to describe the drug resistance (DDS, RIF, OFL) and gene mutation features of leprosy, aiming to provide recommendations for alternative treatment options.

After scoring by the JBI scale, 25 articles were included (score ≥ 5). There were 4349 patients, of which 4128 samples were successfully amplified (94.92%). Experts indicated that the failure of amplification might be attributed to low or absent numbers of bacteria and the presence of PCR inhibitors in the skin. During the treatment process with MDT, the resistance rate for RIF, DDS, and OFL combination was 10.18% (95% CI: 7.85 to 12.51), while the single resistance rates were 4.40% (95% CI: 3.02–5.77), 2.00% (95% CI: 2.48–5.06), and 1.73% (95% CI: 0.99–3.00), respectively. The results are similar to the previous studies [43,44]. For instance, in a large cohort study of leprosy established by several national sentinel testing centers, 8.0% of the strains had varying degrees of resistance (RIF: 3.8%, DDS: 4.5%, OFL: 1.10%, MDR: 1.24%).

We divided the study area into five parts based on the WHO criteria. It could be seen that the highest drug-resistance rate was in the Western Pacific region (17.05%, 95% CI: 7.17–26.93). Few papers from Europe and Africa were included, comprising 11.25% and 16.67%, respectively. Leprosy was almost extinct in Europe, and the first study on AMR in Europe was reported by Chauffour [35]: 18 cases were detected in 160 samples from France between 2001–2015. The results suggested that further studies on drug resistance were needed in Africa. The disease has placed a huge burden on the region, and incomplete MDT coverage or inadequate financial support may account for insufficient research. For example, Sofie MB recruited 1199 leprosy patients in Comoros (African region) between 2017–2019 and found that the patients were not resistant to any antimicrobial drugs [45].

Although the reasons for regional-level variation in resistance are beyond the scope of our study, the findings still reflect differences in antibiotics use (e.g., misuse) or availability. We can hypothesize that the distribution of resistant strains varies between regions, a finding that provides clues to explore the distribution or population mobility of resistant patients. In temporal subgroups, resistance rates were higher after 2009 than before (11.39% vs. 6.59%), which could be related to the global leprosy drug-resistance sentinel surveillance program established by WHO in 2009, resulting in more patients being detected [46]. We found a higher rate of drug resistance in relapsed patients than in new cases (14.26% vs. 7.25%), suggesting that patients were more likely to develop drug resistance if they received MDT for longer periods of time. In addition, we found that there are significant differences in the drug-resistance rates by sample size. Studies with <100 samples had significantly higher resistance rates than studies with ≥100 samples, indicating that sample size was associated with resistance rates.
DDS competes with \textit{para}-aminobenzoate (PABA) and interrupts the function of the DHPS enzyme encoded by Folp1, disrupting folate biosynthesis [47,48]. In this study, the mutation rate of Folp1 was 4.40\% (95\% CI: 3.02–5.77). It is significantly lower than monotherapy for DDS [49]. In other words, leprosy monotherapy is more likely to induce mutations in drug-resistant genes. RIF is also one of the most effective and broad-spectrum antibiotics against leprosy, and the results indicated that the mutation rate of RpoB was 3.66\% (95\% CI: 2.41–4.90). The main mechanism of the drug acts via enzymatic activity inhibition of the β-subunit of RNAP holoenzyme, an enzyme determined by RpoB, which affects mRNA production and causes the death of Mycobacterium leprae [50]. As for the core drug in MDT, the emergence of RIF-resistant strains showed that the effectiveness of current leprosy control strategies is being challenged. DNA gyrase is an important enzyme in Mycobacterium that catalyzes ATP-dependent transient cleavage and negative supercoiling of closed-loop DNA [51]. GyrA determines the protein, and mutations within the gene are associated with resistance to ofloxacin. The mutation rate of GyrA was 1.28\% (95\% CI: 0.87–1.71). However, in a study conducted in Shandong Province, China, the mutation rate was 25.93\%. The high resistance rate may be because the majority of patients in this region are from the rural population, and there is a phenomenon of antibiotic abuse, which leads to primary OFL-resistant strains [22].

Based on the 368 resistance strains, we analyzed the mutation rate of the gene codon. As the results indicated, Pro was the most common mutation locus of Folp1, with a rate of 83.97\% (95\% CI: 77.58–90.37), followed by the codon Thr (ES: 31.36\%, 5.32–57.41). Sundeep also demonstrated that the mutations in target genes mostly involved these two amino acid loci [52]. We found that the pattern of Pro was replaced by Leu with a probability of 41.04\% (95\% CI: 22.76–59.31), followed by Arg (36.80\%, 95\% CI: 17.20–56.40). The highest mutation probability was found at the Ser on RpoB, 54.17\% (53.02–69.40). It has been shown that the dynamics of protein phosphorylation at these two amino acid residues can regulate cellular activities in bacteria and eukaryotes [53]. In addition, the most common mutation pattern was Ser→Leu (42.95\%, 95\% CI: 22.65–63.25), which was also found in Mycobacterium tuberculosis, influenza virus, or \textit{Escherichia coli [54–56]}. Indeed, the mutation feature of Ser→Leu has been demonstrated to significantly reduce the replication and hemagglutinin (HA) cleavage of the H1N2 swine influenza virus and is an influential factor in attenuating viral pathogenicity [57]. Therefore, we speculate that the viability and virulence of RIF-resistant strains will be reduced, but further validation is needed. The mutations in the GyrA target gene were mostly Ala, with a mutation rate of 75.18\% (95\% CI: 68.54 to 88.62). Mutations in Ala can be considered a marker of resistance to OFL in Mycobacterium leprae. Furthermore, Ala→Val was the most common substitution pattern.

In summary, there are three distinctive features of drug resistance in leprosy. First, the global drug-resistance rate to MDT therapies is low, and the number of resistant strains decreases with fewer patients. Second, mutations in the resistance-determining regions of the target genes (Folp1, RpoB, and GyrA) were mainly involved in Pro, Ser, and Ala, and the resistant strains exhibit similar mutation patterns, such as Ser→Leu on RpoB. Similar results have also been found in other mycobacterial genera, such as Mycobacterium tuberculosis [57]. In the studies of resistant strains of \textit{Mycobacterium tuberculosis}, mutations in different codons of RpoB may be associated with different levels of rifampicin resistance. For instance, mutations of Ser were associated with high levels of resistance to rifampicin (minimum inhibitory concentration [MIC] >64 \(\mu\)g/mL). It is well known that \textit{Mycobacterium leprae} and \textit{Mycobacterium tuberculosis} are highly homologous in the DRDR region of the RpoB gene. We can reasonably speculate that the viability and virulence of RIF-resistant strains may be increased. Experts also suggested that the RIF-resistant strains of \textit{Mycobacterium leprae} have become better adapted to the drug and more virulent after RIF treatment [58–60]. Therefore, further validation is needed in future studies. At last, evidence of mutations in the resistance-determining region gene locus of \textit{M. leprae} strains can help clinicians to select alternative treatment options for their patients, such as a combination of RIF, OFL, and clarithromycin. The emergence of resistance to OFL as a complementary therapy has also
caused anxiety in patients. Patients who have never received quinolones for leprosy may have been treated with drugs for other infections, resulting in primary drug resistance [61]. The priority now is to establish a better resistance surveillance policy, careful post-treatment follow-up of cured patients, rapid identification of strains that may develop secondary resistance, earlier detection of recurrent cases and new treatment regimens, and more resistance investigations in endemic areas (e.g., Africa).

The present review has some limitations. Firstly, despite these subgroup analyses, there was still a high degree of heterogeneity in the included studies. This heterogeneity may reflect variability in sample collection methods or size. Secondly, the coverage of studies in some regions was low (e.g., Europe and Africa) and some articles contained a small sample size, which may have affected the final results. Thirdly, the meta-analysis only included drug-resistance mutation loci from these 25 articles, and there may be other mutations that have not yet been identified. At last, there were some potential publication biases in our meta-analysis, such as time lag bias or citation bias.

Supplementary Materials: The supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms232012443/s1.

Author Contributions: L.Z. and P.W. conceived and designed the manuscript. X.L. and G.L. conducted literature research, analysis, and interpretation, compiled tables, and figures, and drafted the manuscript. J.Y., G.J., Y.S. and Y.L. proofed and interpreted the report. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Research Project of China Disabled Persons’ Federation on assistive technology, grant number 2021CDPFAT-46.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: There are no relevant data for this manuscript other than those presented in the paper.

Conflicts of Interest: The author has no relevant relationship or financial involvement with any organization or entity that has a financial interest or financial conflict with the subject matter or material discussed in the manuscript.

References
1. White, C.; Franco-Paredes, C. Leprosy in the 21st Century. Clin. Microbiol. Rev. 2015, 28, 80–94. [CrossRef]
2. WHO. Global leprosy update, 2018: Moving towards a leprosyfree world. Wkly Epidemiol. Rec. 2019, 94, 389–412.
3. Fischer, M. Leprosy—An overview of clinical features, diagnosis, and treatment. JDDG J. Dtsch. Dermatol. Ges. 2017, 15, 801–827. [CrossRef] [PubMed]
4. Chaves, L.; Patriota, Y.; Soares-Sobrinho, J.; Vieira, A.; Lima, S.; Reis, S. Drug Delivery Systems on Leprosy Therapy: Moving Towards Eradication? Pharmaceutics 2020, 12, 1202. [CrossRef]
5. Acebrón-García-de-Eulate, M.; Blundell, T.L.; Vedithi, S.C. Strategies for drug target identification in Mycobacterium leprae. Drug Discov. Today 2021, 26, 1569–1573. [CrossRef] [PubMed]
6. Faust, L.; Klowak, M.; MacRae, C.; Kopalakrishnan, S.; Showler, A.J.; Boggild, A.K. Ofloxacin-Containing Multidrug Therapy in Ambulatory Leprosy Patients: A Case Series. J. Cutan Med. Surg. 2021, 25, 45–52. [CrossRef] [PubMed]
7. Mungroo, M.R.; Khan, N.A.; Siddiqui, R. Mycobacterium leprae: Pathogenesis, diagnosis, and treatment options. Microb. Pathog. 2020, 149, 104475. [CrossRef]
8. Ji, B.; Perani, E.G.; Petinom, C.; Grosset, J.H. Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice. Antimicrob. Agents Chemother. 1996, 40, 393–399. [CrossRef] [PubMed]
9. Machado, D.; Lecorche, E.; Mougarie, F.; Cambau, E.; Viveiros, M. Insights on Mycobacterium leprae Efflux Pumps and Their Implications in Drug Resistance and Virulence. Front. Microbiol. 2018, 9, 3072. [CrossRef] [PubMed]
10. Adams, L.B. Susceptibility and resistance in leprosy: Studies in the mouse model. Immunol. Rev. 2021, 301, 157–174. [CrossRef] [PubMed]
11. Shepard, C.C. The experimental disease that follows the injection of human leprosy bacilli into foot-pads of mice. J. Exp. Med. 1960, 112, 445–454. [CrossRef] [PubMed]
33. Chen, X.; He, J.; Liu, J.; You, Y.; Yuan, L.; Wen, Y. Nested PCR and the TaqMan SNP Genotyping Assay enhanced the sensitivity of drug resistance testing of *Mycobacterium leprae* using clinical specimens of leprosy patients. *PLoS Negl. Trop. Dis.* 2019, 13, e0007946. [CrossRef] [PubMed]

34. Matsuoka, M.; Suzuki, Y.; Garcia, I.E.; Fafutis-Morris, M.; Vargas-González, A.; Carreño-Martinez, C.; Fukushima, Y.; Nakajima, C. Possible mode of emergence for drug-resistant leprosy is revealed by an analysis of samples from Mexico. *Ipn. J. Infect. Dis.* 2010, 63, 412–416. [CrossRef]

35. Chauffour, A.; Lecorche, E.; Reibel, F.; Mougari, F.; Raskine, L.; Aubry, A.; Jarlier, V.; Cambau, E. Prospective study on antimicrobial resistance in leprosy cases diagnosed in France from 2001 to 2015. *Clin. Microbiol. Infect.* 2018, 24, 1213.e5–1213.e8. [CrossRef]

36. Singh, S.; Kumar, A.; Nath, G.; Singh, T.; Mishra, M. Resistance to anti leprosy drugs in multi-bacillary leprosy: A cross sectional study from a tertiary care centre in eastern Uttar Pradesh, India. *Indian J. Dermatol. Venereol. Leprol.* 2018, 84, 275–279. [CrossRef] [PubMed]

37. Matsuoka, M.; Badiawan, T.; Aye, K.S.; Kyaw, K.; Tan, E.V.; Cruz, E.D.; Gelber, R.; Sauderson, P.; Balagon, V.; Pannikar, V. The frequency of drug resistance mutations in *Mycobacterium leprae* isolates in untreated and relapsed leprosy patients from Myanmar, Indonesia and the Philippines. *Lepr. Rev.* 2007, 78, 343–352. [CrossRef]

38. Mejia, M.D.C.C.; Dos Santos, M.P.; da Silva, G.A.V.; Passos, I.D.M.; Naveca, F.G.; Cunha, M.D.G.S.; Moraes, M.O.; de Paula, L. Identification of primary drug resistance to rifampin in *Mycobacterium leprae* strains from leprosy patients in Amazonas State, Brazil. *J. Clin. Microbiol.* 2014, 52, 4359–4360. [CrossRef]

39. Singh, P.; Busso, P.; Paniz-Mondolfi, A.; Aranazau, N.; Monot, M.; Honore, N.; Belone, A.D.F.F.; Virmond, M.; Villarreal-Olaya, M.E.; Rivas, C.; et al. Molecular Drug Susceptibility Testing and Genotyping of *Mycobacterium leprae* Strains from South America. *Antimicrob. Agents Chemother.* 2011, 55, 2971–2973. [CrossRef]

40. Bhattacharya, B.; Reja, A.H.; Biswas, N.; Biswas, S.; Lavania, M.; Chaitanya, V.; Banerjee, S.; Patra, P.M.; Gupta, U.; Patra, P.; et al. Report of rpoB mutation in clinically suspected cases of drug resistant leprosy: A study from Eastern India. *Indian J. Dermatol. Venereol. Leprol.* 2015, 81, 155–161. [CrossRef]

41. Vedithi, S.C.; Lavania, M.; Kumar, M.; Kaur, P.; Turankar, R.P.; Singh, I.; Nigam, A.; Sengupta, U. A report of rifampin-resistant leprosy from northern and eastern India: Identification and in silico analysis of molecular interactions. *Med. Microbiol. Immunol.* 2015, 204, 193–203. [CrossRef]

42. Shi, Y.; Kong, W.; Jiang, H.; Zhang, W.; Wang, C.; Wu, L.; Shen, Y.; Yao, Q.; Wang, H. Molecular Surveillance of Antimicrobial Resistance of *Mycobacterium leprae* from Leprosy Patients in Zhejiang Province, China. *Infect. Drug Resist.* 2022, 15, 4029–4036. [CrossRef] [PubMed]

43. Cambau, E.; Sauderson, P.; Matsuoka, M.; Cole, S.; Kai, M.; Suffys, P.; Rosa, P.; Williams, D.; Gupta, U.; Lavenia, M.; et al. Antimicrobial resistance in leprosy: Results of the first prospective open survey conducted by a WHO surveillance network for the period 2009–15. *Clin. Microbiol. Infect.* 2018, 24, 1305–1310. [CrossRef] [PubMed]

44. Beauvillain, Q.; Lok, C.; Joachim, C.; Hamdad, F.; Lafabregue, E.; Attencourt, C.; Sevestre, H.; Chaby, G. Autochthonous leprosy in Europe: A case report and literature review. *Int. J. Infect. Dis.* 2021, 110, 111–113. [CrossRef]

45. Marijke Braet, S.; Jouet, A.; Aubry, A.; Van Dyck-Lippens, M.; Lenoir, E.; Assoumani, Y.; Baco, A.; Mzbamba, A.; Cambau, E.; Vasconcellos, S.E.G.; et al. Investigating drug resistance of *Mycobacterium leprae* in the Comoros: An observational deep-sequencing study. *Lancet Microbe.* 2022, 3, e693–e700. [CrossRef]

46. WHO. *Guidelines for Global Surveillance of Drug Resistance in Leprosy*: WHO: Delhi, India, 2009.

47. Nisha, J.; Ramanathan, K.; Khan, F.N.; Dhanasekaran, D.; Shanthi, V. Discovery of a potential lead compound for treating leprosy with dapsone resistance mutation in *M. leprae* folP1. *Mol. BioSyst.* 2016, 12, 2178–2188. [CrossRef] [PubMed]

48. Araujo, S.; Goulart, I.R.; Truman, R.W.; Goulart, I.M.B.; Vissà, V.; Li, W.; Matsuoka, M.; Suffys, P.; Fontes, A.B.; Rosa, P.S.; et al. qPCR-High resolution melt analysis for drug susceptibility testing of Mycobacterium leprae directly from clinical specimens of leprosy patients. *PLoS Negl. Trop. Dis.* 2017, 11, e0005506. [CrossRef]

49. Wu, Z.; Wang, C.; Wang, Z.; Shi, Y.; Jiang, H.; Wang, H. Risk factors for Dapsone Resistance in Leprosy Patients: A systematic meta-analysis. *J. Glob. Antimicrob. Resist.* 2022, 30, 459–467. [CrossRef]

50. Lin, W.; Mandal, S.; Degen, D.; Liu, Y.; Ebright, Y.W.; Li, S.; Feng, Y.; Zhang, Y.; Mandal, S.; Jiang, Y.; et al. Structural Basis of *Mycobacterium tuberculosis* Transcription and Transcription Inhibition. *Mol. Cell* 2017, 66, 169–179.e8. [CrossRef]

51. Jiang, H.; Tsang, L.; Wang, H.; Liu, C. Loop-mediated isothermal amplification (LAMP) assay targeting RLEP for detection of *Mycobacterium leprae* in leprosy patients. *Int. J. Infect. Dis.* 2021, 107, 145–152. [CrossRef]

52. Chaitanya, V.S.; Das, M.; Bhat, P.; Ebenezer, M. Computational Modelling of Dapsone Interaction With Dihydropteroate Synthase in *Mycobacterium leprae*: Insights Into Molecular Basis of Dapsone Resistance in Leprosy. *J. Cell Biochem.* 2015, 116, 2293–2303. [CrossRef]

53. Yadav, Y.; Dey, C.S. Ser/Thr phosphatases: One of the key regulators of insulin signaling. *Rev. Endocr. Metab. Disord.* 2022, 23, 905–917. [CrossRef] [PubMed]

54. Fujino, T.; Tozaki, M.; Murakami, H. An Amino Acid-Swapped Genetic Code. *ACS Synth. Biol.* 2020, 9, 2703–2713. [CrossRef] [PubMed]

55. Zaw, M.T.; Emran, N.A.; Lin, Z. Mutations inside rifampicin-resistance determining region of rpoB gene associated with rifampicin-resistance in Mycobacterium tuberculosis. *J. Infect. Public Health* 2018, 11, 605–610. [CrossRef] [PubMed]
56. Steiner, A.; Raheem, S.; Ahmad, Z. Significance of Leu and Ser in the βDELSEED-loop of *Escherichia coli* ATP synthase. *Int. J. Biol. Macromol.* **2020**, *165 Pt B*, 2588–2597. [CrossRef]

57. Pantoja, O. High affinity ammonium transporters: Molecular mechanism of action. *Front. Plant Sci.* **2012**, *3*, 34. [CrossRef]

58. Levis, W.; Rendini, T.; Martiniuk, F. Increasing Virulence in Leprosy Indicated by Global *Mycobacterium* spp. *Emerg. Infect. Dis.* **2018**, *24*, 183–184. [CrossRef]

59. Lin, Y.H.; Tai, C.H.; Li, C.R.; Lin, C.F.; Shi, Z.Y. Resistance profiles and rpoB gene mutations of *Mycobacterium tuberculosis* isolates in Taiwan. *J. Microbiol. Immunol. Infect.* **2013**, *46*, 266–270. [CrossRef]

60. Tupin, A.; Gualtieri, M.; Roquet-Banères, F.; Morichaud, Z.; Brodolin, K.; Leonetti, J.P. Resistance to rifampicin: At the crossroads between ecological, genomic and medical concerns. *Int. J. Antimicrob. Agents* **2010**, *35*, 519–523. [CrossRef]

61. Linder, J.A.; Huang, E.S.; Steinman, M.A.; Gonzales, R.; Stafford, R.S. Fluoroquinolone prescribing in the United States: 1995 to 2002. *Am. J. Med.* **2005**, *118*, 259–268. [CrossRef]